LYNPARZA® (olaparib) More Than Doubled Median Radiographic Progression-Free Survival (rPFS) in BRCA1/2 or ATM Metastatic Castration-Resistant Prostate Cancer vs. Standard of Care (7.4 vs. 3.6 months)

Off Science and Research

Dateline City:
KENILWORTH, N.J.

Merck and AstraZeneca’s LYNPARZA Reduced the Risk of Disease Progression or Death by 51% in Men with Homologous Recombination Repair (HRR) Gene Mutations

First Positive Phase 3 Trial Evaluating a Targeted Treatment in Biomarker-Selected Prostate Cancer Patients

KENILWORTH, N.J.–(BUSINESS WIRE)–AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today presented detailed results from the Phase 3 PROfound trial in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who have a mutation in their homologous recombination repair (HRR) genes and whose disease had progressed on prior treatment with new hormonal agent (NHA) treatments e.g. abiraterone or enzalutamide.

Language:
English

Contact:

Media:
Pamela Eisele
(267) 305-3558
Steve Wanczyk
(267) 305-5563

Investor:
Peter Dannenbaum
(908) 740-1037
Courtney Ronaldo
(908) 740-6132

Ticker Slug:
Ticker:
MRK

Exchange:
NYSE

@Merck

read more

Read Original Article: LYNPARZA® (olaparib) More Than Doubled Median Radiographic Progression-Free Survival (rPFS) in BRCA1/2 or ATM Metastatic Castration-Resistant Prostate Cancer vs. Standard of Care (7.4 vs. 3.6 months) »

About The Author